WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005035779) METHOD
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/035779    International Application No.:    PCT/US2004/033391
Publication Date: 21.04.2005 International Filing Date: 12.10.2004
IPC:
A61K 31/70 (2006.01), A61K 39/00 (2006.01)
Applicants: POWDERJECT VACCINES, INC [US/US]; 2711 Centerville Road, Suite 400, Wilmington, DE 19808 (US) (For All Designated States Except US).
BRAUN, Ralph, Patrick [US/US]; (US) (For US Only).
DONG, Lichun [US/US]; (US) (For US Only)
Inventors: BRAUN, Ralph, Patrick; (US).
DONG, Lichun; (US)
Agent: PEET, Richard, C.; FOLEY & LARDNER, 3000 K Street, N.W., Suite 500, Washington, DC 20007-5143 (US)
Priority Data:
60/510,086 10.10.2003 US
60/526,571 04.12.2003 US
60/567,771 05.05.2004 US
Title (EN) METHOD
(FR) PROCEDE
Abstract: front page image
(EN)The invention relates to a method of eliciting a T cell response against a T cell epitope in a host mammalian subject, which method comprises : (i) a first immunisation that comprises at least two administrations which are from 1 to 14 days apart to the subject, wherein each administration comprises administering a nucleotide of interest (NOI) encoding the T cell epitope, and optionally (ii) a second immunisation that comprises at least one administration to the subject of (a) a NOI encoding the T cell epitope, or (b) a protein comprising the T cell epitope, wherein the time between the first administration of the first immunisation, and the first administration of the second immunisation, is from 21 to 365 days.
(FR)La présente invention concerne un procédé permettant de susciter une réaction lymphocytaire T contre un épitope de lymphocyte T chez un sujet hôte mammifère. A cet effet, on réalise (i) une première immunisation nécessitant deux administrations séparées par 1 à 14 jours d'intervalle. Les deux fois, on administre un nucléotide objet d'étude codant l'épitope du lymphocyte T. On réalise éventuellement (ii) une seconde immunisation par laquelle on administre au sujet considéré (a) un nucléotide objet d'étude codant l'épitope du lymphocyte T ou (b) une protéine comprenant l'épitope du lymphocyte T. Dans ce cas, le délai à respecter entre la première administration de la première immunisation et la première administration de la seconde immunisation est de 21 à 365 jours.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)